Business Context and Reporting Period
Company: Wearable Devices Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of October 2025 (Report dated October 31, 2025)
Principal Executive Offices: 5 Ha-Tnufa Street, Yokne-am Illit, Israel 2066736
This filing reports the execution of a Securities Purchase Agreement on October 29, 2025, for a registered direct offering and a concurrent private placement.
Key Financial Metrics and Transaction Details
The filing details a capital raise transaction rather than standard operating financial results. Key metrics include:
- Total Offering Value: Approximately $3.3 million (as referenced in the press release title).
- Ordinary Shares Issued: 655,000 shares at an offering price of $2.67 per share.
- Pre-Funded Warrants Issued: 575,000 warrants at an offering price of $2.6699 per warrant (exercisable at $0.0001 per share).
- Ordinary Warrants (Private Placement): 1,230,000 warrants issued to the purchaser at an exercise price of $2.67 per share.
- Warrant Amendment: Existing warrants (1,000,000 shares at $4.00 and 670,000 shares at $6.00) were amended to reduce the exercise price to $2.67 per share.
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes and Transaction Structure
The primary material change is the dilution of existing shareholders and the modification of existing warrant terms:
- Beneficial Ownership Limitation: Pre-Funded Warrants were utilized to prevent the purchaser from exceeding a 9.99% beneficial ownership threshold immediately upon closing.
- Lock-Up Provisions: The Company agreed to a 60-day standstill period from the closing date, during which it cannot issue new ordinary shares or equivalent securities (with specific exceptions for Form S-8 and ATM facilities).
- Shareholder Approval Requirements: The issuance of the Ordinary Warrants and the amendment of existing warrants are subject to shareholder approval. The Ordinary Warrants will expire five years from the date of approval.
Guidance, Risks, and Contingencies
Contingencies:
- The closing of the offering and the validity of the warrants are contingent upon shareholder approval.
- The Company must file a registration statement for the Ordinary Warrants within 15 calendar days of shareholder approval and use commercially reasonable efforts to make it effective within 60 days (or 90 days if under full review).
Risks and Forward-Looking Statements:
- The filing contains forward-looking statements regarding the closing of the offering and future business strategies.
- Actual results may differ materially due to uncertainties, including the risk that shareholders may not approve the warrant issuance.
- Reference is made to risks detailed in the Company's Form 20-F for the year ended December 31, 2024.
Investor Verification Checklist
- Verify the final closing date and total net proceeds received from the $3.3 million offering.
- Confirm the outcome of the shareholder vote required to approve the Ordinary Warrants and the Warrant Amendment Agreement.
- Review the impact of the 60-day lock-up period on the Company's ability to raise additional capital via the ATM facility or other means.
- Assess the dilution impact of the 1,230,000 new Ordinary Warrants and the amended existing warrants (1,670,000 shares total) at the reduced exercise price of $2.67.
- Check for any subsequent filings regarding the effectiveness of the registration statement for the Ordinary Warrants.